In 2018, it is estimated that approximately 18 million people worldwide were diagnosed and about 9 million people died from cancer.1
By 2040, new cancer cases worldwide are predicted to almost 30 million.2
“New therapies that save and improve lives are invaluable for patients and their families. We as a Market Access Team, are proudly committed to providing all appropriate patients in Belgium with innovative treatment options as rapidly as possible.”
Eline Darquennes, Market Access Lead MSD Belgium & Luxembourg
“MSD is a world leader in oncology. We are committed to contributing to further progress in cancer treatment, providing hope today and to future generations.”
Olivier Fouret, Director Business Unit Oncology, MSD Belgium & Luxembourg
We believe that one day cancer will be curable. We work with all involved public and private institutions responsible for the treatment and care of patients with cancer to help those affected and their families.
...the participation of patients in clinical trials.
...the support and involvement of the physicians who believe in the importance of advancing the care for patients through innovative clinical trials
...the patient advocacy community who helps support people with cancer through their journeys
In the 1950s, researchers proposed that the immune system patrols the body to detect and destroy tumor cells. Scientists and researchers had previously focused on cancer cells and treating cancer as a genetic disease.
Now the focus is shifting to the microenvironment in which cancer grows, including the immune system – an approach called immuno-oncology.
Immuno-oncology has the potential to change the way cancer is treated and how patients can benefit from it.
(Newly diagnosed cases worldwide in 20183)
We invest in the development of innovative oncological drugs to provide hope to people with cancer. With a focus on immuno-oncology, MSD has one of the largest and fastest growing clinical research programs in the world. MSD is one of the leading companies in research on vaccines, such as cervical cancer.
The ongoing clinical study program in the field of immuno-oncology in Belgium includes 34 clinical studies in various cancers (as of 04/2019).
* Anti-Programmed Death-1
1 http://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf, viewed 14.11.2019
2 http://gco.iarc.fr/tomorrow/home, viewed 14.11.2019
3 http://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf, viewed 14.11.2019